Every year, vast sums of investment capital are lost in the biotech sector — tied up in failed trials, stalled research, and unrealized assets. Zlatomics Fintech has developed a proprietary mechanism to bring that capital back.
Request Early AccessZlatomics Fintech exists to solve a problem that has long been accepted as inevitable: the disappearance of biotech capital from the productive economy. We believe this loss is not inevitable — it is a structural inefficiency, and structural inefficiencies can be corrected. Our mission is to develop the financial tools and mechanisms that make that correction possible.
The biotech sector attracts enormous investment, yet a disproportionate share of that capital never yields returns. Failed drug programs, shelved intellectual property, abandoned datasets, and dissolved companies represent billions in value that simply vanishes from the economy each year — with no recovery mechanism, no structured exit, and no second life.
Zlatomics Fintech has identified a repeatable, scalable approach to recapturing value from biotech assets that the market has written off. Rather than accept permanent loss, we apply a proprietary framework that re-engages dormant assets, restructures how their value is recognized, and channels recovered capital back into the productive economy.
We map the landscape of undervalued and written-off biotech assets — failed programs, shelved IP, and stranded scientific work that still holds latent economic value.
Asset DiscoveryOur proprietary mechanism re-evaluates these assets through a new lens, unlocking pathways to value that conventional finance overlooks.
Proprietary ProcessRecovered value is channeled back into productive use — reinvestment in science, returns to stakeholders, and a healthier, more efficient biotech ecosystem.
Economic RecoveryRequest more information, updates, and early access.